engleski

Combination of CSF protein biomarkers and BDNF, IL10, and IL6 genotypes in early diagnosis of Alzheimer's disease

Cerebrospinal fluid (CSF) biomarkers are mostly used for early detection of Alzheimer’s disease (AD) in the group of patients with mild cognitive impairment (MCI). However, detection of AD in asymptomatic individuals (preclinical AD) is critical. In this study we tested whether the diagnostic potential of core CSF biomarkers (amyloid β42 (Aβ42), total tau (t- tau) and tau phosphorylated at epitope 181 (p- tau181)) could be improved by genetic biomarkers related to inflammatory pathways (IL1α, IL1β, IL10 and IL6) and survival of neurons (BDNF). We compared if levels of Aβ42, t-tau and p-tau181 differed between patients with different BDNF (rs6265), IL1α (rs1800587), IL1β (rs1143623), IL10 (rs1800896) and IL6 (rs1800795) genotypes. Levels of p-tau181 were significantly higher in the mixed group (AD, MCI and control subjects) with GA in comparison to GG BDNF genotype (t = -2.079, df = 221, p = 0.039). Levels of Aβ42 were significantly higher in the group of control subjects with TT in comparison to TC IL10 genotype (t = 2.500, df = 7, p = 0.041), while p-tau181 levels were significantly higher in the group of MCI patients with GC in comparison to CC IL6 genotype (t = -2.300, df = 34, p = 0.028). Thus, the potential of selected BDNF (rs6265), IL10 (rs1800896) and IL6 (rs1800795) polymorphisms in early diagnosis of AD should be further tested and validated on larger cohorts of patients. This work was supported by the Croatian Science Foundation grant. no. IP- 2014-09-9730.

Alzheimer’s disease ; mild cognitive impairment ; BDNF ; IL10 ; IL6

nije evidentirano